elranatamab-bcmm (Elrexfio)
elranatamab-bcmm is an FDA-licensed reference biologic from Pfizer Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
Elrexfio elranatamab-bcmm
Pfizer Inc.
- Approved
- Aug 14, 2023
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for elranatamab-bcmm, in chronological order.
Reference approval
Approval date of the reference elranatamab-bcmm product.
2 yr 10 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 4 yr 3 mo
Frequently asked questions
Are there biosimilars approved for elranatamab-bcmm (Elrexfio)?
No 351(k) biosimilars or interchangeable biosimilars referencing elranatamab-bcmm are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.